Elisa De Paolis, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared on LinkedIn:
“Precision medicine is transforming oncology, but fully understanding the genomic complexity of lung cancer remains a critical challenge. I’m thrilled to share our team’s latest research, just published in Genes MDPI: ‘Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis‘.
In this study, we explored the potential of comprehensive genomic profiling (CGP) in the clinical management NSCLC.
Key findings:
- STK11, TP53, KRAS, and LRP1B mutations are independently associated with poorer survival outcomes.
- The combination of these identifies patient subgroups with an even more unfavorable prognosis and a higher risk of recurrence.
- A significant stage-dependent association emerged between tumor genomics and PD-L1 expression.
- In I-III early-stage tumors, mutations in genes such as PIK3CA, PTEN, and ARID1A correlate with higher PD-L1 expression. Conversely, in advanced stages, alterations in genes like STK11, KEAP1, and ERBB2 are significantly associated with lower levels of PD-L1 expression.
This evidence highlights how essential it is to integrate comprehensive genomic characterization into clinical practice right from diagnosis, allowing for better risk stratification and the optimization of personalized therapeutic strategies.”
Title: Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis.
Authors: Carolina Sassorossi, Elisa De Paolis, Jessica Evangelista, Davide Dalfovo, Alessandra Cancellieri, Ilenia Carriero, Annalisa Campanella, Esther G. C. Troost, Steffen Löck, Róza Ádány, Núria Farré, Ece Öztürk, Rocco Trisolini, Luca Boldrini, Alessio Stefani, Andrea Urbani, Emilio Bria, Stefano Margaritora, Angelo Minucci, Filippo Lococo.
You can also read: Small-Molecule Inhibitors in NSCLC: A 2026 Practical Guide to Drug Interactions and Toxicity.
